Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement
– NMS to receive up to $21 Million
– Financing proceeds will be used to advance NMS’s proprietary PARP1-selective, non-trapping, brain-penetrant, inhibitor NMS-293, as well as its selective PARP7 inhibitor atamparib
NERVIANO, Italy and NEW YORK, NY, March 31, 2025 – Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc., (NMS-US) a wholly owned subsidiary of NMS Srl, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, today announced a transaction with a group of investors, including NovaQuest Capital Management.
This transaction enables NMS to monetize a percentage of future Rozlytrek® (entrectinib) royalties, for an amount up to $21 million. Under the terms of the agreement, after a pre-set return on investment is reached by the purchasers, NMS retains all subsequent royalties tied to Rozlytrek® (entrectinib) global net sales.
“This non-dilutive capital infusion enables NMS to support the development of atamparib, a Phase II- ready selective PARP7 inhibitor we recently in-licensed1, as well as NMS’s potent, proprietary, brain-penetrant, PARP1-selective inhibitor, NMS-293. We reacquired full rights on the asset2, and we are expanding clinical investigation of NMS-293 beyond glioma, namely in small cell lung cancer and ovarian cancer patients3” said Hugues Dolgos, Pharm.D., Chief Executive Officer, NMS.
“We are delighted to partner with NMS and provide funding to support the continued development of their innovative small molecule and ADC platform pipeline,” said Ryan Wooten, Managing Director at NovaQuest. “NMS has brought many innovative oncology therapeutics to market, and we look forward to new products to come.”
Advisors Morgan Stanley & Co. LLC acted as the sole structuring agent.
